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schizophrenic patient is placed, ranging from €67.4 per day in a
day centre, to €164 per day in a long term residency or €315.7
per day in a mental health unit of a general hospital, where most
stays are currently taking place in Spain. CONCLUSIONS: Fol-
lowing the deinstitutionalisation process of psychiatric patients
that has occurred in most Western countries, in Spain, we observe
an increase in admissions rates linked to a decrease in LOS for
schizophrenic patients. The changing patterns of use of hospital
resources parallel to the changes in community care, mean that
the costs have varied complementarily throughout this reform
process. These trends could have important implications for
policy makers and health care providers.
MENTAL HEALTH—Patient-Reported Outcomes Studies
PMH36
WHAT DO PATIENTS WITH SCHIZOPHRENIA WANT OUT OF
THEIR MEDICATION? IDENTIFYING PATIENT REPORTED
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Poor compliance of schizophrenic patients is well known and
linked to negative treatment outcomes. To address persistent
issues of compliance we need to adopt a more patient centric
approach towards evaluation of medicine with an aim to better
appreciate the requirements of patients. OBJECTIVES: To iden-
tify patient requirements towards drug characteristics, with
further emphasis on route of administration, and to examine
if attitudes are modiﬁed with experience with a depot.
METHODS: Based on 13 relevant drug characteristics, extracted
through patient focus groups [n = 20] and literature a survey
instrument was developed. Respondents were asked to rank and
then rate the factors using 5-point Likert scales. Respondents
included depot naïve [n = 33], depot experienced [n = 34], and
patients currently on depot [n = 38]). Data was analyzed using
descriptive statistics. RESULTS: In aggregate, patients ranked
avoidance of dyskinesia (79.25), positive inﬂuence on sleep
(75.25), onset of action (72.75), and no/little weight gain (72.25)
as important drug characteristics. The least rated factors were
no/little interaction with alcohol (52.75) and drug costs (53.5).
With regard to differences between patients experiences with a
depot, current depot users gave frequency of application a higher
ranking (Rank 4 vs. Ranks 8,8). The preference for a depot
formulation was highly dependent on previous experience
(depot: 84%, depot experience: 29%, depot-naïve: 3%, p <
0.05), with an overall preferred frequency of injection every
four weeks. CONCLUSIONS: Patients with Schizophrenia are
capable and willing to share their attitudes about key processes
related to the medical management of schizophrenia. Incorporat-
ing patient preferences into decision making offers an opportu-
nity to better understand issues of adherence and management of
therapy. Experience with a depot medication seems to lead
to higher acceptance and appreciation of such formulations.
More research is need to understand if these differences are
related a optimal selection of medication or a learning by doing
phenomena.
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OBJECTIVES: Considering the patients point of view in treat-
ment decision making is crucial for a successful therapy. In con-
trast to somatic diseases in schizophrenia there are only few
examples where the patients attitude and point of view was
systematically recorded. Objective of the study was to collect the
attitude of schizophrenic patients towards generic substitution of
atypical antipsychotics. METHODS: In the quantitative survey
schizophrenic patients, capable to give one’s consent, aged 18–60
years were interviewed on the basis of a structured questionnaire.
All participants received a second generation antipsychotic for at
least one year. Getting in contact with the patients was facilitated
via practice-based psychiatrists who secured the recruitment of
the appropriate patients in line with the screening criteria.
RESULTS: The survey was conducted in November/December
2007. 104 patients (Æ 41.2  11.1 yrs.; Æ treatment duration
3.5  3.2 yrs.). According to the patients’ information drug
treatment was changed 1.7 times on average during the last 5
years (range 1–14). In case of a generic substitution initiated by
the attending physician 69% of the patients expressed a willing-
ness to take the medication further on. The acceptance of a
treatment switch was reduced if the switch was not justiﬁed by a
lack of efﬁcacy/tolerability (28%). Especially the regular switch
of drugs with the same agent in the pharmacy would be met with
a refusal as voiced by 76% of the patients. CONCLUSIONS: The
study shows that the conduction of a quantitative survey with
schizophrenic patients is feasible and differentiated statements
regarding patients’ attitudes towards pharmacotherapy can be
generated. The results emphasize the importance of an extensive
education of the patients prior to a generic substitution in order
to support therapy adherence, which is fragile per se. Physicians
are expected to fulﬁll this educational task.
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Patient preferences are an important indicator of patients’ under-
lying values and could enlighten literatures on both compliance
and satisfaction with treatment. Patient preference methods,
such as conjoint analysis, are increasingly used in clinical areas,
but applications in mental health remain limited. OBJECTIVES:
To determine the capability of patients with schizophrenia to
complete a conjoint analysis questionnaire, document patients’
reactions to conjoint tasks and assess the validity and reliability
of their responses. METHODS: Attributes and levels relating to
the medical management of schizophrenia were identiﬁed
through patient focus groups and literature reviews to create
simple conjoint analysis task of six attributes with two levels
each. Respondents (n = 25) were patients diagnosed with at least
one episode of schizophrenia, presently stable and undergoing
therapy with a neuroleptic medication and were recruited
through clinics from four cities in Germany. The majority of
respondents were presented with eight paired-comparisons; but
a limited number of respondents were presented with sets of four
scenarios to test satiation. Questionnaires were administered in
person with limited explanation, were audio recorded and later
analyzed. RESULTS: Respondents easily completed the conjoint
tasks and results were consistent with underlying hypotheses.
Speciﬁcally we identiﬁed four statistically signiﬁcant factors: i)
ability to think clearly (p > 0.001); ii) tiredness (p > 0.001); iii)
having a supportive physician (p > 0.001); and iv) the ability to
participate in social activities (p > 0.005). The reliability of
responses based test-retest was high, 82.35% agreement between
responses, Kappa 0.648 (p > 0.0001). Patients could also com-
plete more complicated tasks based on choice among four
Abstracts A591
possible scenarios. CONCLUSIONS: Conjoint analysis can be
used to assess the preferences of patients with schizophrenia,
and such preferences appear valid and relatively consistent.
Although further validation and reﬁnement is needed, our
results indicate that conjoint analysis is a feasible and beneﬁcial
method for measuring patient preferences among patients with
schizophrenia.
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OBJECTIVES: Different instruments are available to assess
health in individuals with psychotic illness. We aimed to identify
the complementary value of some different instruments to assess
health and health changes in schizophrenic patients.
METHODS: We analysed data from a naturalistic, prospective
cohort study, called COMETA, which involved 637 patients aged
18–40 years, 65.0% male, with schizophrenia (86.5%) or schizo-
phreniform disorder (13.5%), enrolled in 2006–2007 and fol-
lowed up to 52 weeks. Symptoms and functional changes were
assessed with the physicians’ rated scales Positive-And-Negative-
Syndrome-Scale (PANSS), Global-Assessment-of-Functioning
(GAF), Clinical-Global-Impression-Severity (CGI-S). The physi-
cians’ opinion was asked to assess compliance toward antipsy-
chotic treatment. Patients reported their attitude toward
treatment with the Drug-Attitude-Inventory (DAI-30). QoL was
assessed with EQ-5D and SF-36. We investigated whether rela-
tionships exist between scores obtained from the different scales.
RESULTS: At enrolment, signiﬁcant correlations were found
between PANSS, GAF, CGI-S scores (r, absolute value = 0.674–
0.766). Every QoL score signiﬁcantly correlated each other (r =
0.360–0.582). Correlations were lower between QoL and clinical
scores (0.189–0.393). Low correlations were estimated between
QoL scores and physicians’ reported compliance (r = 0.113–
0.282) or DAI-30 score (0.142–0.274). Each instrument showed
an average improvement in the patients’ condition after 52
weeks. However, scarce correlation was found between clini-
cians’ and patients’ reported changes. CONCLUSIONS: Both
clinicians’ and patients’ reported outcomes are necessary for a
complete evaluation of schizophrenic patients’ health. Further-
more, its brevity, and its immediateness of data reading and
interpretation are reasons for considering its introduction into
the physicians’ armamentarium for practice.
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OBJECTIVES: To present 2-year results on treatments prescribed
and their impact on quality of life (QoL) and clinical severity of
children with Attention Deﬁcit / Hyperactivity Disorder (ADHD).
METHODS:ADORE is a 2-year, prospective, international obser-
vational study in ADHD. Treatments were classiﬁed as pharma-
cotherapy, psychotherapy, pharmacotherapy and psychotherapy
combination, other, and none. As patients were allowed to change
treatment, different patients may be included in each group at
different endpoints. QoLwasmeasuredwith the ChildHealth and
Illness Proﬁle (CHIP-CE). Clinical ADHD outcomes were mea-
sured with ADHD-Rating scale parent version (ADHD-RS), CGI-
Severity scale, Children’s Global Assessment Scale (CGAS) and
Strengths and Difﬁculties Questionnaire (SDQ). Changes in out-
comes presented hereafter were estimated on all patients followed
2 years and having at least baseline and 24 months visits.
RESULTS: Among 255 French patients eligible for analysis, mean
age (SD) 8.8 years (2.3), 87.5%male, 137 (53.7%) were followed
over 24 months. Treatments were respectively at baseline and 2
years: pharmacotherapy 23.0% & 29.1%, combination
pharmacotherapy/psychotherapy 36.6% & 47.0%, psycho-
therapy 27.2% & 12.7%, other treatment 4.7% & 3.0% and
none 8.5% & 8.2%. Between baseline and 2 years, CHIP-CE
quality of life improved: mean change from baseline was +5.7
(12.9) for satisfaction, +8.6 (11.8) for achievement, +13.4 (13.0)
for risk avoidance, +5.2 (12.4) for resilience and +5.2 (9.6) for
comfort. Between baseline and 2 years, mean ADHD-RS change
was -18.3 (9.9) leading to a ﬁnal score of 21.4 (10.7) at 2 years.
CGAS mean change was +15.8 (15.5) leading to a ﬁnal score of
67.1 (16.2). Mean CGI-S change was -1.5 (1.4) leading to a ﬁnal
score of 3.2 (1.3). Rate of patients with 31 comorbidity decreased
from 76.5% to 54.0% and severity of comorbidities also
decreased. CONCLUSIONS: After 2 years, French patients suf-
fering from ADHD symptoms enrolled in this study beneﬁted
from improvement of QoL and clinical severity. Interpretation is
difﬁcult due to patients changing treatments over the study.
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OBJECTIVES: To explore the association between Sad Blue
Depressed Days (SBDD), health-related quality of life, and health
behaviors among women in a university community in Venezu-
ela. METHODS: A random sample of 71 women ranging in age
from 18 to 72 years was surveyed using a written questionnaire.
The questionnaire included the SBDD question from the Behav-
ioral Risk Factor Surveillance System (BRFSS) and the SF-36
Health Survey. The associations among SBDD, SF-36, demo-
graphics, and health behaviors were estimated computing
Pearson correlation coefﬁcients for continuous variables and
Kendall’s tau for categorical variables. RESULTS: The sample
had a mean age of 31.98 years (s.d.13.86). The prevalence of
alcohol consumption during the previous month was 63.4% and
for smoking it was 16.9%. About 60% of the sample reported no
exercising regularly during the previous month. Most of the
respondents reported sleeping problems. Respondents reported a
mean of 4.33 (s.d.7.89) SBDD in the previous 30 days. Young
women aged 18–24 years reported the highest number of SBDD
(7.51, s.d. 9.80), whereas older women aged 45+ reported the
lowest number (1.50, s.d. 3.86). About 80% of respondents
reported one or more SBDD including 18.3% who reported 14
or more SBDD. The SF-36 showed good internal consistency
reliability. Respondents scored higher in Physical Functioning
(91.76, s.d.10.53) and lower in Vitality (62.25, s.d. 20.07).
SBDD correlated signiﬁcantly with all SF-36 domains, except
Physical Functioning and Bodily Pain. SBDD was associated to
lack of regular exercise, sleeping problems, and poor perception
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